SHOCKWAVE MEDICAL INC (SWAV)
US82489T1043 - Common Stock
Taking everything into account, SWAV scores 6 out of 10 in our fundamental rating. SWAV was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While SWAV has a great health rating, its profitability is only average at the moment. SWAV is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes SWAV very considerable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year SWAV was profitable.
SWAV had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: SWAV reported negative net income in multiple years.
In multiple years SWAV reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of SWAV (9.95%) is better than 93.23% of its industry peers.
Looking at the Return On Equity, with a value of 21.76%, SWAV belongs to the top of the industry, outperforming 95.31% of the companies in the same industry.
The Return On Invested Capital of SWAV (8.81%) is better than 88.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.95% | ||
| ROE | 21.76% | ||
| ROIC | 8.81% |
ROA(3y)13.4%
ROA(5y)-1.2%
ROE(3y)20.17%
ROE(5y)0.98%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SWAV has a Profit Margin of 20.76%. This is amongst the best in the industry. SWAV outperforms 94.79% of its industry peers.
SWAV's Operating Margin of 20.52% is amongst the best of the industry. SWAV outperforms 94.27% of its industry peers.
Looking at the Gross Margin, with a value of 86.99%, SWAV belongs to the top of the industry, outperforming 96.35% of the companies in the same industry.
In the last couple of years the Gross Margin of SWAV has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.52% | ||
| PM (TTM) | 20.76% | ||
| GM | 86.99% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.99%
GM growth 5Y16.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SWAV is destroying value.
SWAV has more shares outstanding than it did 1 year ago.
SWAV has more shares outstanding than it did 5 years ago.
SWAV has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 10.26 indicates that SWAV is not in any danger for bankruptcy at the moment.
The Altman-Z score of SWAV (10.26) is better than 86.98% of its industry peers.
SWAV has a debt to FCF ratio of 4.41. This is a neutral value as SWAV would need 4.41 years to pay back of all of its debts.
SWAV's Debt to FCF ratio of 4.41 is amongst the best of the industry. SWAV outperforms 82.81% of its industry peers.
A Debt/Equity ratio of 0.97 indicates that SWAV is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.97, SWAV is doing worse than 76.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 10.26 |
ROIC/WACC0.94
WACC9.36%
2.3 Liquidity
SWAV has a Current Ratio of 13.81. This indicates that SWAV is financially healthy and has no problem in meeting its short term obligations.
SWAV has a better Current ratio (13.81) than 97.92% of its industry peers.
SWAV has a Quick Ratio of 12.61. This indicates that SWAV is financially healthy and has no problem in meeting its short term obligations.
SWAV has a Quick ratio of 12.61. This is amongst the best in the industry. SWAV outperforms 97.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.81 | ||
| Quick Ratio | 12.61 |
3. Growth
3.1 Past
SWAV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.34%, which is quite good.
SWAV shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.44%.
The Revenue has been growing by 126.31% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)12.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.81%
Revenue 1Y (TTM)41.44%
Revenue growth 3Y120.84%
Revenue growth 5Y126.31%
Sales Q2Q%35.85%
3.2 Future
SWAV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.56% yearly.
The Revenue is expected to grow by 20.10% on average over the next years. This is a very strong growth
EPS Next Y36.11%
EPS Next 2Y27.65%
EPS Next 3Y24.15%
EPS Next 5Y17.56%
Revenue Next Year27.69%
Revenue Next 2Y24.82%
Revenue Next 3Y23.61%
Revenue Next 5Y20.1%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 78.21, SWAV can be considered very expensive at the moment.
Based on the Price/Earnings ratio, SWAV is valued a bit cheaper than the industry average as 67.19% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 28.96, SWAV is valued quite expensively.
With a Price/Forward Earnings ratio of 53.09, SWAV can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SWAV indicates a somewhat cheap valuation: SWAV is cheaper than 68.75% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.82. SWAV is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.21 | ||
| Fwd PE | 53.09 |
4.2 Price Multiples
SWAV's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. SWAV is cheaper than 67.19% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SWAV is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 75.65 | ||
| EV/EBITDA | 66.43 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SWAV does not grow enough to justify the current Price/Earnings ratio.
SWAV has a very decent profitability rating, which may justify a higher PE ratio.
SWAV's earnings are expected to grow with 24.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.17
PEG (5Y)N/A
EPS Next 2Y27.65%
EPS Next 3Y24.15%
5. Dividend
5.1 Amount
No dividends for SWAV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SHOCKWAVE MEDICAL INC
NASDAQ:SWAV (5/30/2024, 8:19:22 PM)
After market: 334.8 +0.05 (+0.01%)334.75
-0.08 (-0.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.57B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.21 | ||
| Fwd PE | 53.09 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)2.17
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.95% | ||
| ROE | 21.76% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 20.52% | ||
| PM (TTM) | 20.76% | ||
| GM | 86.99% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 13.81 | ||
| Quick Ratio | 12.61 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)12.34%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y36.11%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)41.44%
Revenue growth 3Y120.84%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y